Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy.
FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the walls of the chest and lungs.
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma,
$39M Jury Verdict Awarded in Novel Mesothelioma Case
Plaintiffs' lead attorney Mark Linder emphasized this is the first mesothelioma lawsuit that proceeded from this type of ...
FiercePharma4d
J&J talc appeal upends $260M award to Oregon woman with mesothelioma
Three months after a jury awarded $260 million to an Oregon woman who claimed her use of Johnson’s Baby Powder caused her to ...
devdiscourse4d
Judge Overturns $260 Million Verdict Against Johnson & Johnson in Talc Mesothelioma Case
A state judge in Oregon has overturned a $260 million verdict against Johnson & Johnson in a mesothelioma lawsuit. The judge ...
Naturopathic Doctor News3d
Gut Bacteria & Mesothelioma
Mesothelioma, caused by asbestos exposure, is an aggressive form of cancer with no cure; treatments attempt to improve/expand ...
Best Mesothelioma Lawyers Dallas, TX Of 2024
For decades, shipyard workers at Texas ports, Texas oil refinery workers and U.S. soldiers at Dallas-area bases inhaled ...
Monthly Prescribing Reference3d
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
“We’re pleased to offer a new first-line treatment option for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma, a disease where prognoses are generally ...
The Brighterside of News on MSN1d
Breakthrough cancer treatment destroys advanced-stage tumors in under 6 days
Researchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...
Son of Cannock mine worker appealing for help after seeing father's 'unjust' and 'painful' death
The son of a former mining surveyor has spoken of the anguish of discovering his father's asbestos-related cancer diagnosis, ...